Bayer Seeks Stronger Footing In Consumer Health After 2017 Stumble
This article was originally published in The Pink Sheet & The Rose Sheet
Bayer consumer health sales fell 9.1% in Q4 and 2.9% for the year as competitive pressure in the US OTC market, especially from lower-price lines and brands sold on e-commerce sites, cut into sales of its Aleve analgesic and Claritin allergy lines. Heiko Schipper takes over as Bayer's consumer business chief and will lead the division in new initiatives to counter competition with increased marketing support for core brands.
You may also be interested in...
Amazon introduced Basic Care line of cough, cold, allergy and digestive treatment OTCs developed in a partnership with Perrigo. The range could be a major threat to store brand and private label OTCs, though success may depend on whether consumers wait for Amazon deliveries or shop at stores.
Bayer hires Heiko Schipper away from Nestle's nutritional products business to succeed Erica Mann as its consumer division chief. Mann intended to resign at the end of 2018 but will step down early because Schipper will take the division top spot in March.
“There is a ton of work still for us to do,” Erica Mann, Bayer’s global consumer head, said after the firm reported disappointing second-quarter results. The root of the problem is over-estimating the revenue boost from former Merck & Co. brands, the firm says.